HeartBeam Corp (BEAT) - Earnings growth forecast for next year

heartbeam.com - graphic logo of issuer BEAT

The current valuation of HeartBeam, Inc. (BEAT) EPS growth for the coming year reflects expert expectations, with 21.90 representing the current metric. HeartBeam, Inc. (BEAT) revenues are based on the sale of compact 3D-ECG systems for the rapid diagnosis of myocardial infarctions. Business success relies on FDA approval and the accuracy of ischemia detection. Stable demand in cardiology protects financial results from macroeconomic downturns.

BEAT: HeartBeam Corp Earnings growth forecast for next year 07/04/2022 - 11/14/2026

HeartBeam - analytical breakdowns and key metrics (BEAT)

- share price and consensus valuation forecast:
Stock Price HeartBeam, Inc.|BEAT - Price Target Chart
- market capitalization indicators:
Market Capitalization HeartBeam|BEAT - Total Enterprise Value
- book capitalization indicators:
Book Value per Share HeartBeam|BEAT - Book Capitalization|Market Value to Book Value Ratio heartbeam.com|BEAT - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio HeartBeam, Inc.|BEAT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital HeartBeam Corporation|BEAT - Company Total Debt Obligations|Debt to Book Capitalization Ratio HeartBeam Corporation|BEAT - Company Long-Term Indebtedness|Company Short-Term Debts HeartBeam|Quick Liquidity Indicator heartbeam.com
- earnings and valuation multiples information:
BEAT - Net Financial Result|Projected Future Earnings HeartBeam, Inc.|BEAT - Price to Earnings Ratio|Forward P/E Multiple HeartBeam Corporation|BEAT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple HeartBeam, Inc.|BEAT - Operating profit EBITDA|Net earnings per share for the last 12 months HeartBeam|BEAT - Earnings per share for the last four quarters|Quarterly EPS earnings growth heartbeam.com|BEAT - Earnings per share increase in current year|Earnings growth forecast for next year HeartBeam, Inc.
- revenue and sales proceeds data:
BEAT - Company Total Revenue|Projected Sales Volume HeartBeam Corporation|BEAT - P/S Multiple|Price-to-Projected Revenue Ratio HeartBeam Corp
Initial company analysis:BEAT, HeartBeam
Brand item of heartbeam.com

The fundamental valuation of an asset is based on the business's ability to generate future cash flow. This indicator aggregates expert consensus forecasts for earnings per share growth rates; therefore, changes in analyst EPS growth estimates reflect market optimism regarding profitability. For HeartBeam, Inc. (BEAT), the dynamics of this metric depend directly on the pace of user base expansion and the acquisition of FDA certifications for its cloud software.

Competing companies

REGN (Regeneron Pharmaceuticals, Inc.) - Earnings growth forecast for next year|IRTC: Expected earnings per share trend next year|Expected earnings per share growth for next year LNTH (lantheus.com)|Net earnings per share growth forecast for next year MLYS (Mineralys Therapeutics Inc)|Net earnings per share growth forecast for next year HeartFlow HTFL|KMTS - Expected earnings per share growth for next year|ESPR: Expected earnings per share growth for next year|Expected net earnings per share growth next year amarincorp.com|AVR: Earnings growth forecast for next year|Expected net earnings per share growth next year Tenaya Therapeutics Inc (TNYA)|Expected earnings per share growth for next year CVRX|Milestone Pharma - Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year Cardiol Therapeutics Inc (CRDL)|TENX: Net earnings per share change forecast for next year|Earnings growth forecast for next year ADGM (adagiomedical.com)|BCDA - Expected earnings per share growth for next year|Catheter Precision Corporation - Earnings growth forecast for next year|ABIO - Earnings growth forecast for next year|ACST: Earnings growth forecast for next year|Net earnings per share change forecast for next year AVTE (Aerovate Therapeutics)|VERV (Verve Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Windtree Therapeutics, Inc. WINT